Qulipta (atogepant) is FDA approved for both chronic and episodic migraine prevention in adults. Ongoing data shows safety and promising results in patients who've failed multiple other preventives.

The 778-subject PROGRESS trial tested Qulipta in migraine patients who had been experiencing headache on 15 or more days per month, for at least three months, with AbbVie's drug given as either 60 ...

Analysts at GlobalData have said they expect Qulipta to get approval for chronic migraine prevention in 2023, helping it to sales of $1.2 billion by 2027, with growth coming particularly among ...

It’s a pill you take daily. Qulipta is approved for both the prevention of episodic migraine and chronic migraine. The same contraindications as the other small-molecule CGRP inhibitors apply ...

Nurtec ODT contains rimegepant, Ubrelvy contains ubrogepant, and Qulipta contains atogepant. Ubrelvy and Nurtec ODT are used to treat migraine episodes that occur with or without aura. Nurtec ODT ...

There are many other products AbbVie can count on, from migraine medicine Qulipta to its Botox franchise. And, of course, investors can expect the company to earn brand-new approvals, be it thanks ...

The drugmaker has other important growth drivers, too. Qulipta and Ubrelvy especially stand out, with sales for the two migraine therapies skyrocketing 76% and 30% year over year, respectively ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.